<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01928563</url>
  </required_header>
  <id_info>
    <org_study_id>DA8159_DIP_I</org_study_id>
    <nct_id>NCT01928563</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Udenafil and Dapoxetine</brief_title>
  <official_title>A Randomized, Open-label, Crossover Study to Investigate the Pharmacokinetic Drug Interaction Between Udenafil and Dapoxetine in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dong-A ST Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dong-A ST Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to investigate the pharmacokinetic drug interaction between Udenafil
      and Dapoxetine in healthy male subjects

      Design : Randomized, open-label, 3-treatment, 6-sequence, 3-period crossover study

      Investigational Product : Udenafil, Dapoxetine
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax and AUClast of Udenafil and Dapoxetine</measure>
    <time_frame>Blood gathering point : 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 32, 48h (each period)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-00, Tmax, T1/2β of Udenafil and Dapoxetine AUClast, Cmax, Tmax, t1/2β of DA-8164(major metabolite of Udenafil) and Desmethyl dapoxetine(major metabolite of Dapoxetine)</measure>
    <time_frame>0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 32, 48h (each period)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Healthy Male Subjects</condition>
  <arm_group>
    <arm_group_label>Dapoxetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapoxetine is administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Udenafil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Udenafil is administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Udenafil and Dapoxetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Udenafil and Dapoxetine are co-administered</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapoxetine</intervention_name>
    <arm_group_label>Dapoxetine</arm_group_label>
    <other_name>Brand name : Priligy</other_name>
    <other_name>Dapoxetine is administered</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Udenafil</intervention_name>
    <arm_group_label>Udenafil</arm_group_label>
    <other_name>Brand name : Zydena</other_name>
    <other_name>Code name : DA-8159</other_name>
    <other_name>Udenafil is administered</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Udenafil+Dapoxetine</intervention_name>
    <arm_group_label>Udenafil and Dapoxetine</arm_group_label>
    <other_name>Udenafil and Dapoxetine are co-adminstered</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male volunteers in the age between 20 and 45 years old at screening

          -  Body mass index(BMI) in the range of 19 to 27 ㎏/㎡

          -  Sitting position blood pressure down to meet the criteria at the time of screening
             (90mmHg≤Systolic blood pressure≤140mmHg)

        Exclusion Criteria:

          -  History of clinically significant disease or kidney, liver and biliary system,
             digestive system, respiratory, musculoskeletal, endocrine, neurological psychiatric
             blood and tumor system, cardiovascular system, etc.

          -  History of gastrointestinal diseases or gastrointestinal operation which might affect
             the study drug absorption

          -  Clinically significant hypersensitivity or with a history of hypersensitivity
             reactions to Udenafil, Dapoxetine ingredients that included elements of the same
             family of drugs, or other medications

          -  ≥ 1.5 fold of normal upper limit(UNL) in the level of ALT, AST

          -  Alcohol, excessive intake (&gt;21 units/week)

          -  Excessive smoker (&gt;10 cigarette/day)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyun-Seop Bae, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yong-Goo Bae, MSc</last_name>
    <phone>+82-2-920-8521</phone>
    <email>byg@donga.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Songpa-gu</state>
        <zip>138-786</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kyun-Seop Bae, M.D., Ph.D.</last_name>
      <phone>+82-2-3010-4611</phone>
      <email>ksbae@amc.seoul.kr</email>
    </contact>
    <investigator>
      <last_name>Kyun-Seop Bae, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 21, 2013</study_first_submitted>
  <study_first_submitted_qc>August 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2013</study_first_posted>
  <last_update_submitted>August 21, 2013</last_update_submitted>
  <last_update_submitted_qc>August 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Udenafil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

